Welcome to our dedicated page for Cvrx SEC filings (Ticker: CVRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CVRx, Inc. filings document a Nasdaq-listed medical device company commercializing Barostim neuromodulation therapy for cardiovascular disease. Its Form 8-K reports record financial results releases, preliminary operating updates, material agreements, equity offering arrangements, amendments to its loan and security agreement, and executive compensation actions tied to performance stock units.
Proxy filings describe annual meeting matters, director elections, auditor ratification, board structure and stockholder voting procedures. The company’s SEC record also identifies its common stock, emerging growth company status, governance disclosures and capital-structure matters associated with debt and at-the-market equity financing.
CVRx, Inc. reported first-quarter 2026 revenue of $14.8 million, up 20% from $12.3 million a year earlier, driven mainly by U.S. heart failure sales. U.S. revenue rose to $13.7 million as implanting centers and sales territories expanded, while European revenue was roughly flat.
Gross margin improved to 87% from 84% as manufacturing efficiencies lowered cost per unit. Operating expenses increased modestly, and the company recorded a net loss of $13.1 million, slightly better than the prior-year loss. Cash and cash equivalents were $72.3 million, and term loan borrowings rose to $60.0 million after a January 2026 amendment expanded the facility to $100.0 million and extended maturity to 2031. Management expects continued operating losses as it invests in commercialization of its Barostim neuromodulation device.
CVRx, Inc. reported first quarter 2026 revenue of $14.8 million, up 20% from $12.3 million a year earlier, driven mainly by U.S. sales growth. U.S. revenue reached $13.7 million, while Europe contributed $1.1 million.
Gross profit was $12.9 million with gross margin improving to 87% from 84%. Operating expenses rose to $25.0 million, and net loss was $13.1 million, or $0.50 per share, slightly better than the $13.8 million, or $0.53 per share, loss in 2025. Cash and cash equivalents totaled $72.3 million at March 31, 2026.
The company activated the first site and enrolled the first patient in its BENEFIT-HF trial, which is designed to assess whether Barostim can help a broader group of heart failure patients. For the second quarter of 2026, CVRx expects revenue between $15.1 million and $16.1 million and maintained its full-year 2026 revenue and expense guidance while updating its gross margin outlook.
CVRx, Inc. is asking stockholders to vote at a fully virtual 2026 annual meeting on June 1, 2026. Investors will elect three Class II directors (including CEO Kevin Hykes and new nominee Michael Dale) for terms through 2029 and ratify Grant Thornton as independent auditor for 2026.
The proxy details governance practices, director and executive pay, and stock ownership. CVRx remains an “emerging growth company” and expects to lose that status on December 31, 2026, which will increase future reporting requirements.
CVRx, Inc. reported preliminary first quarter 2026 results showing total revenue of $14.7–$14.8 million, up from $12.3 million a year earlier, which is about 20% growth. Gross margin is expected to improve to roughly 87% from 84%, while total operating expenses are projected at about $25 million versus $23.7 million.
As of March 31, 2026, CVRx had 257 U.S. active implanting centers and 56 U.S. sales territories, and held approximately $72.3 million in cash and cash equivalents. The company highlights improved reimbursement after Category I CPT codes took effect, with 30‑day Medicare Advantage prior authorization approval rates rising from 31% in 2024 to 44% in 2025 and 50% for the first two months of 2026.
CVRx also activated the first site in its BENEFIT‑HF randomized trial on March 31, 2026, with enrollment expected to begin in the second quarter. If successful, this study could expand the indicated patient population for Barostim by about three times.
CVRx, Inc. reported that Chief Medical Officer Philip B. Adamson received new equity awards and completed a small share sale tied to tax withholding. On February 27, 2026, he was granted stock options for 62,000 shares of common stock at an exercise price of $8.16 per share, expiring on February 26, 2036, along with 41,000 restricted stock units. The restricted stock units vest 25% on each annual anniversary of the grant date, and the options vest 25% on February 27, 2027 with the remainder vesting monthly thereafter. On March 2, 2026, he sold 1,262 shares of common stock at a weighted average price of about $7.90 per share in multiple trades between $7.90 and $8.00, a sale that was mandated by the award agreement to satisfy tax withholding obligations through a sell-to-cover transaction. Following these transactions, he directly held 61,578 common shares.
Morrison Gregory reported acquisition or exercise transactions in this Form 4 filing.
CVRx, Inc. reported that Chief Human Resources Officer Gregory Morrison received equity awards on March 2, 2026. He was granted 154,500 stock options and 34,000 shares of common stock at no cost. The common stock represents restricted stock units vesting 25% annually, while the options vest 25% on March 2, 2027 and monthly thereafter.
CVRx, Inc. filed an initial statement of beneficial ownership for executive Gregory Morrison, who serves as Chief Human Resources Officer. This Form 3 establishes his status as an insider of the company and provides the baseline disclosure of his equity holdings for future reporting under securities rules.
CVRx, Inc. president and CEO Kevin Hykes reported both an equity award and a small tax-related sale. He received a grant of 238,000 stock options and 159,000 restricted shares, which vest over several years. To cover tax withholding from these awards, he sold 7,763 common shares at a weighted average price of $7.9027 per share in mandated sell-to-cover transactions. After these trades, he directly owned 284,237 common shares.
CVRx, Inc. Chief Marketing & Strategy Officer Paul Verrastro reported a mix of equity grants and a small sale. On February 27, 2026, he acquired 45,000 shares of common stock as restricted stock units and a 67,000-share stock option grant, both at no cost.
The restricted stock units vest 25% on each annual anniversary of the grant date, while the option vests 25% on February 27, 2027 and then monthly in equal installments. On March 2, 2026, he sold 1,284 shares of common stock at a weighted average price of $7.9021 per share, in transactions ranging from $7.90 to $7.98, to satisfy tax withholding obligations through a mandated sell-to-cover transaction. Following the sale, he directly held 60,551 shares of common stock and 67,000 stock options.
CVRx, Inc. chief financial officer Jared Oasheim reported a mix of equity grants and a small mandated share sale. He received a grant of 91,000 stock options at an exercise price of $0.0000 per share, vesting 25% on February 27, 2027 and then monthly thereafter. He was also granted 61,000 shares of common stock in the form of restricted stock units that vest 25% on each annual anniversary of the grant date. To cover tax withholding obligations from these awards, he sold 1,744 shares of common stock in an open-market sell-to-cover transaction on March 2, 2026 at a weighted-average price of $7.9022 per share, with individual sale prices ranging from $7.90 to $7.9831. After these transactions, he directly held 96,703 shares of common stock.